Submit manuscript

Comparison of Ondansetron-Dexamethasone-Lorazepam versus Metoclopramide-Dexamethasone-Lorazepam in the Control of Cisplatin Induced Emesis

SUMONMAL MANUSIRIVITHAYA, M.D.*, VIRUCH CHAREONIAM, M.D.**, PAWARES ISARIYODOM,M.D.**, DANAI SUNGSAB, M.D. **

Affiliation : *Department of Obstetrics and Gynecology, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok 10300, **Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

Abstract
The antiemetic effect of ondansetron-dexamethasone-lorazepam versus those of meto clopramide-dexamethasone-lorazepam were evaluated in 30 ovarian cancer patients undergoing treatment with the same chemotherapeutic regimen (c isplatin 60 mg/m2 and cyclophosphamide 700 mg/m2 Patients were randomly selected to receive either the ondansetron arm or the metoclopramide arm in their first cycle of chemotherapy, but were given an alternative combination in the second cycle. In the ondansetron arm, ondansetron was given 8 mg intravenously (IV) plus dexamethasone 20 mg IV and lorazepam 0.5 mg oral. For the metoclopramide arm, metocloprarnide 10 mg was given IV plus dexamethasone 20 mg IV and lorazepam 0.5 mg oral. All antiemetics were given twice ; 30 minutes before and 6 hours after chemotherapy. In the metoclopramide arm, metoclopramide 40 mg continuous infusion was also administered. During the acute phase, the ondansetron combination was significantly superior to the metocloprarnide combination for all evaluation parameters. Complete control of emesis was 90 per cent vs 36.7 per cent, complete pro tection from nausea was 80 per cent vs 43.3 per cent, and complete protection from both nausea and vomiting was 73.3 per cent vs 30.0 per cent. Forty per cent of patients in the ondansetron arm did not complain of any adverse reaction compared to 13.4 per cent in the metoclopramide arm. It can be concluded, therefore, that a combination of ondansetron, dexamethasone and lorazepam appears to provide a significantly better emetic control with less adverse reaction than the metoclo pramide combination in the acute nausea-vomiting phase after receiving cisplatin.

Keywords : Cisplatin, Emesis, Ondansetron, Metoclopramide


All Articles Download


INFORMATION

Contact info

JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
4th Floor, Royal Golden Jubilee Building,
2 Soi Soonvijai, New Petchburi road,
Bangkok 10310, Thailand.
Phone: 0-2716-6102, 0-2716-6962
Fax: 0-2314-6305
Email: editor@jmatonline.com

JMed Assoc Thai
MEDICAL ASSOCIATION OF THAILAND
ISSN: 0125-2208 (Print),
ISSN: 2408-1981 (Online)
The content of this site is intended for health professionals.

Submissions

» Online Submissions » Author Guidelines » Copyright Notice » Privacy Statement

Other

» Journal Sponsorship » Site Map » About this Publishing System

© MEDICAL ASSOCIATION OF THAILAND. All Rights Reserved. The content of this site is intended for health professionals.